-
Mashup Score: 1
Pisit “Duke” Pitukcheewanont, MD, Lumos Pharma, discusses a phase 2 trial evaluating LUM-201 for treatment of growth hormone deficiency.
Source: CheckRare.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1
Pisit “Duke” Pitukcheewanont, MD, Lumos Pharma, discusses a phase 2 trial evaluating LUM-201 for treatment of growth hormone deficiency.
Source: CheckRare.comCategories: General Medicine News, Oncologists1Tweet-
Pisit “Duke” Pitukcheewanont, MD, Chief Medical Officer for Lumos Pharma, discusses a phase 2 trial evaluating LUM-201 (ibutamoren) for treatment of growth hormone deficiency. #CheckRare #RareDisease #GHD https://t.co/0eIL1iNPho
-
-
Mashup Score: 1
John Carmichael, MD, discusses an analysis of growth hormone replacement therapy in patients under the age of 60 years.
Source: CheckRare.comCategories: General Medicine News, Oncologists1Tweet-
John Carmichael, MD, Co-director of the USC Pituitary Center and Clinical Chief for the Division of Endocrinology, discusses an analysis of growth hormone replacement therapy in patients under the age of 60 years. #CheckRare #RareDisease #GHD https://t.co/9mic6KCf9A
-
-
Mashup Score: 1
Pisit “Duke” Pitukcheewanont, MD, Lumos Pharma, discusses a phase 2 trial evaluating LUM-201 for treatment of growth hormone deficiency.
Source: CheckRare.comCategories: General Medicine News, Oncologists1Tweet-
Pisit “Duke” Pitukcheewanont, MD, Chief Medical Officer for Lumos Pharma, discusses a phase 2 trial evaluating LUM-201 (ibutamoren) for treatment of growth hormone deficiency. #CheckRare #RareDisease #GHD https://t.co/0eIL1iNPho
-
-
Mashup Score: 1
John Carmichael, MD, discusses an analysis of growth hormone replacement therapy in patients under the age of 60 years.
Source: CheckRare.comCategories: General Medicine News, Oncologists1Tweet-
John Carmichael, MD, Co-director of the USC Pituitary Center and Clinical Chief for the Division of Endocrinology, discusses an analysis of growth hormone replacement therapy in patients under the age of 60 years. #CheckRare #RareDisease #GHD https://t.co/9mic6KCf9A
-
-
Mashup Score: 1
Pisit “Duke” Pitukcheewanont, MD, Lumos Pharma, discusses a phase 2 trial evaluating LUM-201 for treatment of growth hormone deficiency.
Source: CheckRare.comCategories: General Medicine News, Oncologists1Tweet-
Pisit “Duke” Pitukcheewanont, MD, Chief Medical Officer for Lumos Pharma, discusses a phase 2 trial evaluating LUM-201 (ibutamoren) for treatment of growth hormone deficiency. #CheckRare #RareDisease #GHD https://t.co/0eIL1iNPho
-
-
Mashup Score: 1
John Carmichael, MD, discusses an analysis of growth hormone replacement therapy in patients under the age of 60 years.
Source: CheckRare.comCategories: General Medicine News, Oncologists1Tweet-
John Carmichael, MD, Co-director of the USC Pituitary Center and Clinical Chief for the Division of Endocrinology, discusses an analysis of growth hormone replacement therapy in patients under the age of 60 years. #CheckRare #RareDisease #GHD https://t.co/9mic6KCf9A
-
-
Mashup Score: 1
Pisit “Duke” Pitukcheewanont, MD, Lumos Pharma, discusses a phase 2 trial evaluating LUM-201 for treatment of growth hormone deficiency.
Source: CheckRare.comCategories: General Medicine News, Oncologists1Tweet-
Pisit “Duke” Pitukcheewanont, MD, Chief Medical Officer for Lumos Pharma, discusses a phase 2 trial evaluating LUM-201 (ibutamoren) for treatment of growth hormone deficiency. #CheckRare #RareDisease #GHD https://t.co/0eIL1iNPho
-
-
Mashup Score: 1
John Carmichael, MD, discusses an analysis of growth hormone replacement therapy in patients under the age of 60 years.
Source: CheckRare.comCategories: General Medicine News, Oncologists1Tweet-
John Carmichael, MD, Co-director of the USC Pituitary Center and Clinical Chief for the Division of Endocrinology, discusses an analysis of growth hormone replacement therapy in patients under the age of 60 years. #CheckRare #RareDisease #GHD https://t.co/9mic6KCf9A
-
Pisit “Duke” Pitukcheewanont, MD, Chief Medical Officer for Lumos Pharma, discusses a phase 2 trial evaluating LUM-201 (ibutamoren) for treatment of growth hormone deficiency. #CheckRare #RareDisease #GHD https://t.co/0eIL1iNPho